The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Product Labeling

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Product Labeling


High impact information on Product Labeling


Biological context of Product Labeling


Anatomical context of Product Labeling


Associations of Product Labeling with chemical compounds

  • (iii) Indirect product labeling of released aldehyde groups by hydrazone formation with an acridone-labeled hydrazide [12].
  • CONCLUSIONS: The use of statins in a clinical practice led to observed reductions in LDL cholesterol level that were significantly less than those projected by package insert guidelines [13].
  • Removal from product labeling of a warning against coadministration of ritonavir and alprazolam was based on a previous study only of extended exposure to ritonavir, in which CYP3A induction offset inhibition [14].
  • Among patients who started troglitazone therapy in 1998 (after the incorporation of a boxed warning and increased monitoring requirements in the product labelling), the estimated risk of liver-related death is approximately 1 in 100,000 [15].
  • For these reasons, the C2/C6 ratio is of clinical relevance and should be included in the product labeling in the future [16].

Gene context of Product Labeling

  • Similar to NSAIDs, warnings on reproduction have been included in the product labelling of marketed COX-2-specific inhibitors [17].
  • METHODS: Data were collected in a noninterventional prospective fashion on patients with RA who qualified for the PCT treatment per the package insert [18].
  • MAIN OUTCOME MEASURES: The appropriateness of CSF use was assessed, based on consensus-derived indication guidelines and the Food and Drug Administration-approved product labeling [19].
  • Each SGA (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole) will be described for its prolactin effects, documented sexual disturbances associated with use, and product labeling regarding sexual function [20].
  • Our review enabled us to characterize the clinical presentation and the treatment received, which were not described in the package insert or by the IFN beta (interferon beta-1b) Multiple Sclerosis Study Group publication [21].

Analytical, diagnostic and therapeutic context of Product Labeling


  1. Felbamate: clinical and molecular aspects of a unique antiepileptic drug. Brown, W.M., Aiken, S.P. Critical reviews in neurobiology. (1998) [Pubmed]
  2. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. Ballow, C.H., Jones, R.N., Johnson, D.M., Deinhart, J.A., Schentag, J.J. Diagn. Microbiol. Infect. Dis. (1997) [Pubmed]
  3. Accuracy of the Vitek system for antimicrobial susceptibility testing Enterobacteriaceae bloodstream infection isolates: use of "direct" inoculation from Bactec 9240 blood culture bottles. Putnam, L.R., Howard, W.J., Pfaller, M.A., Koontz, F.P., Jones, R.N. Diagn. Microbiol. Infect. Dis. (1997) [Pubmed]
  4. Evaluation of the dofetilide risk-management program. Allen LaPointe, N.M., Chen, A., Hammill, B., DeLong, E., Kramer, J.M., Califf, R.M. Am. Heart J. (2003) [Pubmed]
  5. A primer of drug safety surveillance: an industry perspective. Part II: Product labeling and product knowledge. Allan, M.C. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. (1992) [Pubmed]
  6. Use of terfenadine and contraindicated drugs. Thompson, D., Oster, G. JAMA (1996) [Pubmed]
  7. Use of oral contraceptives by women with epilepsy. Mattson, R.H., Cramer, J.A., Darney, P.D., Naftolin, F. JAMA (1986) [Pubmed]
  8. The safety and efficacy of the estrogen patient package insert. A questionnaire study. Udkow, G.P., Lasagna, L., Weintraub, M., Tamoshunas, Z. JAMA (1979) [Pubmed]
  9. Public judgments of information in a diazepam patient package insert. Fisher, S., Mansbridge, B., Lankford, D.A. Arch. Gen. Psychiatry (1982) [Pubmed]
  10. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. Saito, M., Hirata-Koizumi, M., Urano, T., Miyake, S., Hasegawa, R. Journal of clinical pharmacy and therapeutics. (2005) [Pubmed]
  11. Do urine dipsticks reliably predict microhematuria? The bloody truth! Moore, G.P., Robinson, M. Annals of emergency medicine. (1988) [Pubmed]
  12. A general assay for antibody catalysis using acridone as a fluorescent tag. Reymond, J.L., Koch, T., Schröer, J., Tierney, E. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  13. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Frolkis, J.P., Pearce, G.L., Nambi, V., Minor, S., Sprecher, D.L. Am. J. Med. (2002) [Pubmed]
  14. Alprazolam-ritonavir interaction: implications for product labeling. Greenblatt, D.J., von Moltke, L.L., Harmatz, J.S., Durol, A.L., Daily, J.P., Graf, J.A., Mertzanis, P., Hoffman, J.L., Shader, R.I. Clin. Pharmacol. Ther. (2000) [Pubmed]
  15. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Plosker, G.L., Faulds, D. Drugs (1999) [Pubmed]
  16. HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Treib, J., Haass, A., Pindur, G., Seyfert, U.T., Treib, W., Grauer, M.T., Jung, F., Wenzel, E., Schimrigk, K. Thromb. Haemost. (1995) [Pubmed]
  17. A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy. Chan, V.S. Drug safety : an international journal of medical toxicology and drug experience. (2004) [Pubmed]
  18. Effects of Prosorba column apheresis in patients with chronic refractory rheumatoid arthritis. Roth, S. J. Rheumatol. (2004) [Pubmed]
  19. Surveillance of colony-stimulating factor use in US academic health centers. Yim, J.M., Matuszewski, K.A., Vermeulen, L.C., Ratko, T.A., Burnett, D.A., Vlasses, P.H. The Annals of pharmacotherapy. (1995) [Pubmed]
  20. Sexuality and schizophrenia: a review. Kelly, D.L., Conley, R.R. Schizophrenia bulletin. (2004) [Pubmed]
  21. Interferon beta-1b injection site reactions and necroses. Gaines, A.R., Varricchio, F. Mult. Scler. (1998) [Pubmed]
  22. Ceftazidime dosing in the elderly: economic implications. Vlasses, P.H., Bastion, W.A., Behal, R., Sirgo, M.A. The Annals of pharmacotherapy. (1993) [Pubmed]
  23. Hepatic safety of itraconazole. Gupta, A.K., Chwetzoff, E., Del Rosso, J., Baran, R. Journal of cutaneous medicine and surgery. (2002) [Pubmed]
WikiGenes - Universities